Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 7/20 | 0.46 |
| ▸ | TACR1 | P25103 | 3/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1494352 | 0.92 | HTR7 (0.46) | HTR7TACR1OPRM1MEN1KMT2A | |
| SCHEMBL1494040 | 0.83 | HTR7 (0.45) | HTR7TACR1OPRM1MEN1KMT2A | |
| SCHEMBL1186148 | 0.83 | ADRA1D (0.58) | HTR7TACR1OPRM1MEN1KMT2A | |
| SCHEMBL1185948 | 0.81 | TACR1 (0.54) | HTR7TACR1OPRM1MEN1KMT2A | |
| SCHEMBL1494387 | 0.81 | HTR7 (0.44) | HTR7TACR1OPRM1MEN1KMT2A | |
| SCHEMBL1186118 | 0.79 | TACR1 (0.51) | HTR7TACR1OPRM1MEN1KMT2A | |
| SCHEMBL21669397 | 0.78 | HTR1A (0.61) | HTR7TACR1OPRM1ADRA1DADRA1A | |
| Fumaric Acid SCHEMBL1185462 | 0.78 | TACR1 (0.55) | HTR7TACR1OPRM1MEN1KMT2A | |
| SCHEMBL1492353 | 0.77 | HTR7 (0.49) | HTR7ADRA1DADRA1AADRA1B | |
| Fumaric Acid SCHEMBL1186320 | 0.77 | TACR1 (0.52) | HTR7TACR1OPRM1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220604-A1 | PIPERAZINYL-ALKYL-BENZOIMIDAZOL-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2012-08-30 | — | — | US | claimed |
| WO-2011032903-A1 | PIPERAZINYL-ALKYL-BENZOIMIDAZOL-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2011-03-24 | — | — | WO | claimed |
| US-20120220604-A1 | PIPERAZINYL-ALKYL-BENZOIMIDAZOL-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2012-08-30 | — | — | US | disclosed |
| WO-2011032903-A1 | PIPERAZINYL-ALKYL-BENZOIMIDAZOL-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220604-A1 | PIPERAZINYL-ALKYL-BENZOIMIDAZOL-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC18A3 | HTR7 61/4885TACR1 108/4885OPRM1 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.